Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 12/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15945384 | 1.00 | PDE10A (0.43) | PDE10AKDM4ECA12CA1CA2 | |
| SCHEMBL14059267 | 1.00 | PDE10A (0.43) | PDE10AKDM4ECA12CA1CA2 | |
| SCHEMBL20424129 | 0.87 | PDE10A (0.38) | PDE10AKDM4ECA12CA1CA2 | |
| SCHEMBL29058062 | 0.87 | PDE10A (0.38) | PDE10AKDM4ECA12CA1CA2 | |
| SCHEMBL20443854 | 0.87 | PDE10A (0.38) | PDE10AKDM4ECA12CA1CA2 | |
| SCHEMBL29058061 | 0.87 | PDE10A (0.38) | PDE10AKDM4ECA12CA1CA2 | |
| SCHEMBL15945386 | 0.86 | GPR88 (0.42) | PDE10A | |
| SCHEMBL14149174 | 0.86 | GPR88 (0.42) | PDE10A | |
| SCHEMBL14149186 | 0.86 | CA1 (0.38) | PDE10AKDM4ECA12CA1CA2 | |
| SCHEMBL14060062 | 0.86 | CA1 (0.38) | PDE10AKDM4ECA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206703-A1 | PROCESS FOR PREPARING ((1S,2S)-2-(5-METHYLPYRIDIN-2-YL)CYCLOPROPYL)METHANOL | MERCK SHARP & DOHME LLC (US) | 2025-06-26 | — | — | US | disclosed |
| EP-4504703-A1 | PROCESS FOR PREPARING ((1S,2S)-2-(5-METHYLPYRIDIN-2-YL)CYCLOPROPYL)METHANOL | Merck Sharp & Dohme LLC (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023192170-A1 | PROCESS FOR PREPARING ((1S,2S)-2-(5-METHYLPYRIDIN-2-YL)CYCLOPROPYL)METHANOL | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206703-A1 | PROCESS FOR PREPARING ((1S,2S)-2-(5-METHYLPYRIDIN-2-YL)CYCLOPROPYL)METHANOL | ADH1C, ADH1A, CYP2S1 | PDE10A 2635/4885KDM4E 618/4885CA12 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.